Private-public alliance for the common good

Merck gets funding from GAVI to produce Ebola vaccine

Like Comment

A private-public deal will fund Merck&Co to produce, stockpile and attain approval for an Ebola vaccine that showed promising results last year, Nature and Science report. GAVI, a swiss organization that helps poor countries vaccinate children, announced yesterday at the World Economic Forum in Davos, Switzerland, that it will provide US $5 million to make this possible.

This vaccine is currently being used to vaccinate all known contacts of the recent Sierra Leone Ebola victim.

Nonia Pariente

Chief Editor, Nature Microbiology

I come from a mid-sized city on the northwestern coast of Spain. My interest in science initially took me to Madrid, where I finished university and received a PhD in molecular biology. In Madrid, I studied RNA virus evolution and new antiviral strategies with Esteban Domingo. I then moved to UCLA, where I focused on developing lentiviral vectors for gene therapy in Irvin Chen’s laboratory. In 2007, I made the plunge from bench to desk and joined the EMBO Reports editorial team as Reviews Editor, becoming Scientific Editor two years later and Senior Editor in 2012. At EMBO Reports, I was responsible for microbiology and immunology, among other areas, and spent many years expanding my understanding and love for all things microbial. In the summer of 2015, I joined the Nature Microbiology editorial launch team, handling all things related to virology and mycology (and for a brief while parasitology) and -after a couple of stints covering microbiology at Nature- I became the Chief Editor of Nature Microbiology in 2019. I look forward to interacting with the community and providing a venue to publish the most important advances in the field.